Process Initiated For CHF P3 Interim Analysis
Filed with ASX · · 2 pages · English
Story so far
Earlier from Mesoblast
- Mesoblast Raises US$40 Million
- Durable Three Year Outcomes in Disc Disease
- FDA Grants Mesoblast Fast Track Designation For GVHD
- Positive Nine Month RA Results For Mesoblast Cell Therapy
- Published Results Show MSB Cells Effective In RA Model
Later from Mesoblast
- FDA Clears Heart Disease Trial At Boston Childrens Hospital
- Mesoblast Receives A$3.7m From Aus Govt For R&D
- Successful Interim Analysis in Phase 3 Heart Failure Trial
- Third Quarter Financial Results On Form 6-K
- MSB Provides Q3 Operational Highlights and Financial Results
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast